Skip to main content
Erschienen in: Rheumatology International 3/2007

01.01.2007 | Original Article

Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies

verfasst von: Sara Kashef, Mohammad Mehdi Ghaedian, Akbar Rajaee, Abbas Ghaderi

Erschienen in: Rheumatology International | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Dyslipoproteinemia is common in lupus patients. In this study, we investigated the pattern of dyslipoproteinemia in the course of active systemic lupus erythematosus (SLE) in possible association with anti-double-stranded DNA (anti-dsDNA) antibodies. Forty-six lupus patients under 45 years old who fulfilled the American College of Rheumatology revised criteria for the classification of SLE were selected. The exclusion criteria were renal failure, nephrotic syndrome, thyroid or liver disease, diabetes mellitus, obesity, pregnancy and taking drugs that induce dyslipidemia. Disease activity was measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Comparison of the lipid profiles, between active and inactive groups determined high levels of serum TG and VLDL and low levels of serum HDL in active group in comparison with inactive group(P < 0.05). The results indicated that the levels of TG and VLDL were significantly elevated in the patients with positive anti-dsDNA (P < 0.05). Although, the mean of serum HDL levels was also lower in patients with positive anti-dsDNA, the difference was not significant. This pattern of dyslipoproteinemia in active SLE may be associated with the autoimmune mechanisms especially in relation to the presence of anti-dsDNA antibodies.
Literatur
1.
Zurück zum Zitat Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R (2001) Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 10:359–363PubMedCrossRef Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R (2001) Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 10:359–363PubMedCrossRef
2.
Zurück zum Zitat Ettinger WH, Goldberg AP, Appelbaum-Bowden D, Hazzard WR (1987) Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 83:503–508PubMedCrossRef Ettinger WH, Goldberg AP, Appelbaum-Bowden D, Hazzard WR (1987) Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 83:503–508PubMedCrossRef
3.
Zurück zum Zitat Petri M (2000) Detection of coronary artery disease and role of traditional risk factors in the Hopkins lupus Cohort. Lupus 9(3):170–175PubMedCrossRef Petri M (2000) Detection of coronary artery disease and role of traditional risk factors in the Hopkins lupus Cohort. Lupus 9(3):170–175PubMedCrossRef
4.
Zurück zum Zitat Leong KH, Koh ET, Feng PH, Boey ML (1994) Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21:1264–1267PubMed Leong KH, Koh ET, Feng PH, Boey ML (1994) Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21:1264–1267PubMed
5.
Zurück zum Zitat Lahita RG, Rivkin E, Cavanagh I, Romano P (1993) Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36:1566–1574PubMed Lahita RG, Rivkin E, Cavanagh I, Romano P (1993) Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36:1566–1574PubMed
6.
Zurück zum Zitat Ilowite NT, Samuel P, Ginzler E, Jacobson MS (1988) Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859–863PubMed Ilowite NT, Samuel P, Ginzler E, Jacobson MS (1988) Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859–863PubMed
7.
Zurück zum Zitat Borba EF, Bonfá E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533–539PubMed Borba EF, Bonfá E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533–539PubMed
8.
Zurück zum Zitat Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M (2002) Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46:2957–2963PubMedCrossRef Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M (2002) Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46:2957–2963PubMedCrossRef
9.
Zurück zum Zitat Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed
10.
Zurück zum Zitat Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Committee on prognosis studies in SLE. Derivation of the SLEDAI a: disease activity index for lupus patients. Arthritis Rheum 35:630–640PubMed Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Committee on prognosis studies in SLE. Derivation of the SLEDAI a: disease activity index for lupus patients. Arthritis Rheum 35:630–640PubMed
11.
Zurück zum Zitat Warnick GR, Benderson J, Albers JJ (1982) Dextran sulfate–Mg2 + precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 28:1379–1388PubMed Warnick GR, Benderson J, Albers JJ (1982) Dextran sulfate–Mg2 + precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 28:1379–1388PubMed
12.
Zurück zum Zitat Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin chem 18:499–502PubMed
13.
Zurück zum Zitat Gharavi AV, Lockshin MD (1997) Antiphospholipid antibodies. In: Rose NR, Macario EC, Folds JD, et al (eds) manual of clinical laboratory, 5th edn, ASM press Immunology, Washington DC, pp 949–953 Gharavi AV, Lockshin MD (1997) Antiphospholipid antibodies. In: Rose NR, Macario EC, Folds JD, et al (eds) manual of clinical laboratory, 5th edn, ASM press Immunology, Washington DC, pp 949–953
14.
Zurück zum Zitat Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J (2003) Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/ tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48:2533–2540PubMedCrossRef Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J (2003) Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/ tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48:2533–2540PubMedCrossRef
15.
Zurück zum Zitat Ilowite NT, Copperman N, Leicht T, Kwong T, Jacobson MS (1995) Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol 22:1347–1351PubMed Ilowite NT, Copperman N, Leicht T, Kwong T, Jacobson MS (1995) Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol 22:1347–1351PubMed
16.
Zurück zum Zitat Ginsberg HN (1990) Lipoprotein physiology and its relationship to atherogenesis. Endocrinol Metab Clin North Am 19:211–228PubMed Ginsberg HN (1990) Lipoprotein physiology and its relationship to atherogenesis. Endocrinol Metab Clin North Am 19:211–228PubMed
17.
Zurück zum Zitat Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC. Chylomicron (2000) Metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43:1033–1040PubMedCrossRef Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC. Chylomicron (2000) Metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43:1033–1040PubMedCrossRef
18.
Zurück zum Zitat Beaumont JL, Berard M, Antonucci M, Delplanque B, Vranckx R (1997) Inhibition of lipoprotein lipase activity by a monoclonal immunoglobulin in autoimmune hyperlipidemia. Atherosclerosis 26:67–77CrossRef Beaumont JL, Berard M, Antonucci M, Delplanque B, Vranckx R (1997) Inhibition of lipoprotein lipase activity by a monoclonal immunoglobulin in autoimmune hyperlipidemia. Atherosclerosis 26:67–77CrossRef
19.
Zurück zum Zitat Alverson DC, Chase HP (1977) Systemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J Pediatr 91:72–75PubMedCrossRef Alverson DC, Chase HP (1977) Systemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J Pediatr 91:72–75PubMedCrossRef
20.
Zurück zum Zitat Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, Isenberg DA (2002) Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46:2686–2694PubMedCrossRef Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, Isenberg DA (2002) Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46:2686–2694PubMedCrossRef
21.
Zurück zum Zitat Abe H, Tsuboi N, Suzuki S, Sakuraba H, Takanashi H, Tahara K,Tonozuka N,Hayashi T, Umeda M (2001) Anti- apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatol 28:990–995PubMed Abe H, Tsuboi N, Suzuki S, Sakuraba H, Takanashi H, Tahara K,Tonozuka N,Hayashi T, Umeda M (2001) Anti- apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatol 28:990–995PubMed
22.
Zurück zum Zitat Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG (1998) Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7:355–360PubMedCrossRef Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG (1998) Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7:355–360PubMedCrossRef
23.
Zurück zum Zitat Lazarevic MB, Vitic J, Myones BL, Mladenovic V, Nanusevic N, Skosey JL, Swedler WI (1993) Antilipoprotein antibodies in rheumatoid arthritis. Semin Arthritis Rheum 22:385–391PubMed Lazarevic MB, Vitic J, Myones BL, Mladenovic V, Nanusevic N, Skosey JL, Swedler WI (1993) Antilipoprotein antibodies in rheumatoid arthritis. Semin Arthritis Rheum 22:385–391PubMed
24.
Zurück zum Zitat Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC (1999) Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 18:17–22PubMedCrossRef Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC (1999) Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 18:17–22PubMedCrossRef
25.
Zurück zum Zitat Semb H, Peterson J, Tavernier J, Olivecrona T (1987) Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol chem 262:8390–8394PubMed Semb H, Peterson J, Tavernier J, Olivecrona T (1987) Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol chem 262:8390–8394PubMed
26.
Zurück zum Zitat Beutler BA, Cerami A (1985) Recombinant interleukin-1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 135:3969–3971PubMed Beutler BA, Cerami A (1985) Recombinant interleukin-1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 135:3969–3971PubMed
27.
Zurück zum Zitat Ehnholm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, Pakkarainen J, Cantell K (1982) Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 2:68–73PubMed Ehnholm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, Pakkarainen J, Cantell K (1982) Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 2:68–73PubMed
28.
Zurück zum Zitat Kwiterovich PO Jr (1998) The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82:13Q–21QPubMedCrossRef Kwiterovich PO Jr (1998) The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82:13Q–21QPubMedCrossRef
29.
Zurück zum Zitat Third report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III): final report. Circulation 106:3143–3420 Third report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III): final report. Circulation 106:3143–3420
Metadaten
Titel
Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies
verfasst von
Sara Kashef
Mohammad Mehdi Ghaedian
Akbar Rajaee
Abbas Ghaderi
Publikationsdatum
01.01.2007
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 3/2007
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-006-0195-3

Weitere Artikel der Ausgabe 3/2007

Rheumatology International 3/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.